NCT04813497View on ClinicalTrials.gov

Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members

NACompletedINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Covid19
Interventions
DIAGNOSTIC_TEST

Serology to determine SARS-CoV-2 infection

Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Trial Locations (1)

6060

Grand Hôpital de Charleroi, Charleroi

All Listed Sponsors
lead

Grand Hôpital de Charleroi

OTHER

NCT04813497 - Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members | Biotech Hunter | Biotech Hunter